PSA/KLK3/Kallikrein 3/Prostate Specific Antigen CRISPR/Cas9 KO Plasmid (h): sc-400448

Overview

KLK3 encodes kallikrein-related peptidase 3 (PSA), a secreted serine protease produced predominantly by prostate luminal epithelial cells and released into seminal fluid. PSA participates in proteolytic processing of seminal plasma proteins and contributes to extracellular protease networks that modulate substrate cleavage, protein turnover, and microenvironmental signaling. Its expression is strongly regulated by androgen receptor signaling, linking KLK3 transcription to hormonal control of prostate epithelial differentiation and secretory programs. Dysregulated KLK3 expression and altered PSA activity are closely associated with prostate pathobiology and are widely used as molecular readouts in studies of androgen response, tumor progression, and microenvironment remodeling.

PSA/KLK3/Kallikrein 3/Prostate Specific Antigen CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the KLK3 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the KLK3 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.

The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the KLK3 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish PSA/KLK3/Kallikrein 3/Prostate Specific Antigen protein expression.

This CRISPR knockout system enables efficient generation of KLK3-deficient cell models for investigation of PSA/KLK3/Kallikrein 3/Prostate Specific Antigen signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.

Key Features

• sgRNAs targeting KLK3 exon(s) critical for PSA/KLK3/Kallikrein 3/Prostate Specific Antigen function
• Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
• GFP reporter for identification of transfected cells
• Pool of plasmids targeting multiple KLK3 genomic sites to improve knockout efficiency
• Compatible with delivery by transfection

Design Variants

CRISPRs +/- HDRs

• gRNAs encoded by PSA/KLK3/Kallikrein 3/Prostate Specific Antigen CRISPR/Cas9 KO Plasmid (h) and PSA/KLK3/Kallikrein 3/Prostate Specific Antigen CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the KLK3 locus. One or both targeting designs may be available. See Related Products for availability.
• HDR donor constructs encoded by PSA/KLK3/Kallikrein 3/Prostate Specific Antigen HDR Plasmid (h) and PSA/KLK3/Kallikrein 3/Prostate Specific Antigen HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by KLK3 homology arms to support homology-directed repair at defined KLK3 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.

For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.